QC
REGN icon

Quent Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Quent Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$282K Sell
366
-112
-23% -$85.7K 0.02% 305
2025
Q4 		$369K Buy
478
+38
+9% +$25.8K 0.03% 267
2025
Q3 		$248K Buy
440
+2
+0.5% +$1.13K 0.02% 245
2025
Q2 		$230K Buy
438
+39
+10% +$21.8K 0.02% 249
2025
Q1 		$253K Sell
399
-22
-5% -$15.1K 0.03% 215
2024
Q4 		$300K Buy
421
+2
+0.5% +$1.68K 0.03% 195
2024
Q3 		$440K Buy
419
+8
+2% +$8.9K 0.04% 197
2024
Q2 		$432K Buy
411
+21
+5% +$20.4K 0.05% 185
2024
Q1 		$375K Buy
390
+19
+5% +$18.1K 0.04% 212
2023
Q4 		$326K Buy
371
+14
+4% +$11.5K 0.04% 216
2023
Q3 		$294K Buy
357
+24
+7% +$18.9K 0.05% 215
2023
Q2 		$239K Buy
333
+7
+2% +$5.4K 0.04% 244
2023
Q1 		$268K Buy
326
+3
+0.9% +$2.26K 0.05% 224
2022
Q4 		$233K Buy
323
+15
+5% +$11.1K 0.04% 237
2022
Q3 		$212K Buy
308
+4
+1% +$2.52K 0.04% 238
2022
Q2 		$180K Sell
304
-17
-5% -$11.1K 0.04% 248
2022
Q1 		$224K Sell
321
-922
-74% -$583K 0.04% 255
2021
Q4 		$785K Buy
+1,243
New +$764K 0.17% 104

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Quent Capital's REGN Position: Q1 2026 in Review

Quent Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 23% in Q1 2026, selling an estimated $85.7K and leaving 366 shares worth $282K. The position accounts for 0.02% of the portfolio, ranked #305.

Quent Capital first reported a position in REGN in Q4 2021 and has held it in 18 quarters since. The position peaked at $785K in Q4 2021. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Quent Capital held 366 shares of Regeneron Pharmaceuticals worth $282K as of Q1 2026.
  • Quent Capital sold 112 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $85.7K.
  • Regeneron Pharmaceuticals made up 0.02% of Quent Capital's portfolio in Q1 2026, its #305 holding.
  • Quent Capital first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Quent Capital's Regeneron Pharmaceuticals position peaked at $785K in Q4 2021.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Quent Capital's 13F filing for Q1 2026, filed 28 Apr 2026.